According to the latest report by IMARC Group, titled “Influenza Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” offers a comprehensive analysis of the industry, which comprises insights on the global influenza diagnostics market share. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The global influenza diagnostics market size reached US$ 893.4 Million in 2022. Looking forward, IMARC Group expects the market to reach a value of US$ 1,461.7 Million on by 2028, exhibiting a growth rate (CAGR) of 6.55% during 2023-2028.
Influenza or flu is a highly contagious infectious disease caused by a virus. It affects the nose, throat, and lungs and causes severe aches and fever. It is diagnosed through immunofluorescence assays, serology, viral culture, rapid antigen testing, rapid influenza diagnostic tests (RIDTs), reverse transcription polymerase chain reaction (RT-PCR), and rapid molecular assays. These procedures include several immunoassay tests to detect the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and provide the result in a qualitative way as positive or negative. As a result, influenza diagnostic solutions are extensively adopted in hospitals and diagnostic laboratories across the globe.
Request For Sample Report: https://www.imarcgroup.com/influenza-diagnostics-market/requestsample
Key Industry Trends and Drivers:
The market is primarily driven by the growing prevalence of chronic diseases that increases the risk of influenza, including cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis. In addition, the increasing popularity of the rapid influenza diagnostic test (RIDT), which is convenient to use and offers results in fewer minutes, is accelerating the product adoption rate across the globe.
Moreover, the introduction of technologically advanced influenza diagnostics tests integrated with a combo of influenza A and B and coronavirus disease (COVID-19) rapid antigen tests represents another major growth-inducing factor. Besides this, the rising integration of artificial intelligence (AI) in influenza diagnostics to reduce timelines for sample processing and facilitate error-free results are providing a positive thrust to the market growth. Furthermore, the rising geriatric population prone to respiratory tract infections and the implementation of various government policies to reduce the risk of influenza are propelling market growth.
who are the key players/companies in key factors driving market?
Aisin Corporation, Akebono Brake Industry Co. Ltd., BorgWarner Inc., Brembo S.p.A., Continental AG, Haldex AB, HELLA GmbH & Co. KGaA (Faurecia SE), Hitachi Ltd., Hyundai Mobis Co. Ltd. (Hyundai Motor Group), Knorr-Bremse AG, Performance Friction Corporation, Robert Bosch GmbH and ZF Friedrichshafen AG.
The report has been segmented the market into following categories:
Breakup by Product:
· Test Kit and Reagents
Breakup by Test Type:
· Molecular Diagnostic Tests
o Polymerase Chain Reaction
o Isothermal Nucleic Acid Amplification Tests
o Other Molecular Tests
· Traditional Diagnostic Tests
o Rapid Influenza Diagnostic Tests
o Viral Culture Tests
o Direct Fluorescent Antibody Test
o Serological Tests
Breakup by Type of Flu:
· Type A Flu
· Type B Flu
· Type C Flu
Breakup by End User:
· Diagnostic Laboratories
- Asia Pacific
- North America
- Middle East and Africa
- Latin America
On the geographical front, Asia Pacific enjoys the leading position in the market. This can be attributed to the rising establishment of international companies in the region, on account of low manufacturing costs and cheap labor
Ask An Analyst: https://www.imarcgroup.com/request?type=report&id=6053&flag=C
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R Sheridan,
WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 |
Africa and Europe :- +44-702-409-7331 |
Asia: +91-120-433-0800, +91-120-433-0800